Is Pharmagen Stock a Good Investment?
Pharmagen Investment Advice | PHRX |
- Examine Pharmagen's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pharmagen's leadership team and their track record. Good management can help Pharmagen navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Stock space and any emerging trends that could impact Pharmagen's business and its evolving consumer preferences.
- Compare Pharmagen's performance and market position to its competitors. Analyze how Pharmagen is positioned in terms of product offerings, innovation, and market share.
- Check if Pharmagen pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pharmagen's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pharmagen stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pharmagen is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Pharmagen Stock
Researching Pharmagen's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years. Pharmagen had 45:1 split on the 7th of December 2011.
To determine if Pharmagen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pharmagen's research are outlined below:
| Pharmagen generated a negative expected return over the last 90 days | |
| Pharmagen has high historical volatility and very poor performance | |
| Pharmagen has some characteristics of a very speculative penny stock | |
| Pharmagen has a very high chance of going through financial distress in the upcoming years | |
| Pharmagen currently holds 2.16 M in liabilities. Pharmagen has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Pharmagen's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 4.81 M. Net Loss for the year was (6 M) with profit before overhead, payroll, taxes, and interest of 2.75 M. | |
| Pharmagen currently holds about 264.67 K in cash with (692.07 K) of positive cash flow from operations. |
Pharmagen's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 361.95 K.Pharmagen's profitablity analysis
The company has Profit Margin (PM) of (1.33) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.31.Determining Pharmagen's profitability involves analyzing its financial statements and using various financial metrics to determine if Pharmagen is a good buy. For example, gross profit margin measures Pharmagen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pharmagen's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pharmagen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pharmagen. Check Pharmagen's Beneish M Score to see the likelihood of Pharmagen's management manipulating its earnings.
Basic technical analysis of Pharmagen Stock
As of the 20th of March, Pharmagen holds the Risk Adjusted Performance of (0.11), variance of 169.49, and Coefficient Of Variation of (768.11). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharmagen, as well as the relationship between them.Pharmagen's Outstanding Corporate Bonds
Pharmagen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pharmagen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pharmagen bonds can be classified according to their maturity, which is the date when Pharmagen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PHARMACIA P 66 Corp BondUS71713UAW27 | View | |
| PHARMACIA P 675 Corp BondUS71713UAT97 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Pharmagen's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pharmagen's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 3.33 | |||
| Coefficient Of Variation | (768.11) | |||
| Standard Deviation | 13.02 | |||
| Variance | 169.49 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (1.47) | |||
| Total Risk Alpha | (0.61) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 100.0 | |||
| Skewness | (7.68) | |||
| Kurtosis | 59.0 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 3.33 | |||
| Coefficient Of Variation | (768.11) | |||
| Standard Deviation | 13.02 | |||
| Variance | 169.49 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (1.47) | |||
| Total Risk Alpha | (0.61) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 100.0 | |||
| Skewness | (7.68) | |||
| Kurtosis | 59.0 |
Pharmagen Stock media impact
Far too much social signal, news, headlines, and media speculation about Pharmagen that are available to investors today. That information is available publicly through Pharmagen media outlets and privately through word of mouth or via Pharmagen internal channels. However, regardless of the origin, that massive amount of Pharmagen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pharmagen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pharmagen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pharmagen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pharmagen alpha.
Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.